These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1923 related articles for article (PubMed ID: 33734448)
1. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors. Drews SJ; Devine DV; McManus J; Mendoza E; Manguiat K; Wood H; Girardin R; Dupuis A; McDonough K; Drebot M Transfusion; 2021 May; 61(5):1440-1446. PubMed ID: 33734448 [TBL] [Abstract][Full Text] [Related]
2. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations. Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484 [TBL] [Abstract][Full Text] [Related]
4. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Schlickeiser S; Schwarz T; Steiner S; Wittke K; Al Besher N; Meyer O; Kalus U; Pruß A; Kurth F; Zoller T; Witzenrath M; Sander LE; Müller MA; Scheibenbogen C; Volk HD; Drosten C; Corman VM; Hanitsch LG Front Immunol; 2020; 11():628971. PubMed ID: 33584731 [TBL] [Abstract][Full Text] [Related]
5. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion. Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD Front Immunol; 2021; 12():739037. PubMed ID: 34594341 [TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105 [TBL] [Abstract][Full Text] [Related]
7. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China. Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199 [TBL] [Abstract][Full Text] [Related]
8. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216 [TBL] [Abstract][Full Text] [Related]
9. Convalescent plasma treatment of critically ill intensive care COVID-19 patients. Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412 [TBL] [Abstract][Full Text] [Related]
10. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay. Goodhue Meyer E; Simmons G; Grebe E; Gannett M; Franz S; Darst O; Di Germanio C; Stone M; Contestable P; Prichard A; Reik R; Vassallo R; Young P; Busch MP; Williamson P; Dumont LJ Transfusion; 2021 Apr; 61(4):1160-1170. PubMed ID: 33554362 [TBL] [Abstract][Full Text] [Related]
11. Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors. Annen K; Morrison TE; DomBourian MG; McCarthy MK; Huey L; Merkel PA; Andersen G; Schwartz E; Knight V Transfusion; 2021 Apr; 61(4):1148-1159. PubMed ID: 33452828 [TBL] [Abstract][Full Text] [Related]
12. Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma. Girardin RC; Dupuis AP; Payne AF; Sullivan TJ; Strauss D; Parker MM; McDonough KA J Infect Dis; 2021 Mar; 223(5):743-751. PubMed ID: 33417696 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing Antibody Responses in COVID-19 Convalescent Sera. Lee WT; Girardin RC; Dupuis AP; Kulas KE; Payne AF; Wong SJ; Arinsburg S; Nguyen FT; Mendu DR; Firpo-Betancourt A; Jhang J; Wajnberg A; Krammer F; Cordon-Cardo C; Amler S; Montecalvo M; Hutton B; Taylor J; McDonough KA J Infect Dis; 2021 Jan; 223(1):47-55. PubMed ID: 33104179 [TBL] [Abstract][Full Text] [Related]
14. Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors. Martin MC; Jimenez A; Ortega N; Parrado A; Page I; Gonzalez MI; Blanco-Peris L PLoS One; 2022; 17(2):e0264124. PubMed ID: 35202394 [TBL] [Abstract][Full Text] [Related]
16. Resistance of SARS-CoV-2 beta and gamma variants to plasma collected from Canadian blood donors during the spring of 2020. Drews SJ; Abe KT; Hu Q; Samson R; Gingras AC; Colwill K; Rathod B; Wang J; Fazel-Zarandi M; Yi QL; Robinson A; Wood H; Tuite A; Fisman D; Evans DH; Lin YJ; O'Brien SF Transfusion; 2022 Jan; 62(1):37-43. PubMed ID: 34662434 [TBL] [Abstract][Full Text] [Related]
17. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160 [TBL] [Abstract][Full Text] [Related]
18. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671 [TBL] [Abstract][Full Text] [Related]